Home/Syntrix Pharmaceuticals/Stuart Kahn, MD

SK

Stuart Kahn, MD

Medical Director

Syntrix Pharmaceuticals

Therapeutic Areas

Oncology Pain Autoimmunity

Syntrix Pharmaceuticals Pipeline

Drug	Indication	Phase
SX-682	Oncology (Immuno-oncology)	Clinical Development
Desmetramadol	Pain	Clinical Development

Leadership Team at Syntrix Pharmaceuticals

John A. Zebala, MD, PhD

President and CEO

Dean Y. Maeda, PhD

Director Medicinal Chemistry and Preclinical Development

View full Syntrix Pharmaceuticals profile